• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Platelets >In vitroeffect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
【24h】

In vitroeffect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

机译：单独的EltromboPag体育效果，并与肌细胞扩增综合征患者的巨淀粉组合在巨淀粉中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results. We aimed to quantify the colony forming units of megakaryocytes (CFU-Mk) obtained from CD34+ bone marrow cells isolated from patients with MDS and from healthy donors that were culturedin vitroin the presence or absence of azacitidine and with or without the sequential addition of eltrombopag to the culture medium. CD34+ bone marrow cells from 6 MDS patients and 3 controls were expandedin vitroand cultured for 3 days with or without azacitidine. Subsequently, a CFU-Mk assay was performed in presence or absence of eltrombopag. The addition of eltrombopag in the CFU-Mk assay after mock treatment of CD34+ cells increased the number of CFU-Mk in both controls and patients. On the contrary, using azacitidine pretreated CD34+ cells, eltrombopag minimally increased CFU-Mk in controls and produced heterogeneous response in MDS patients with no change in two patients and CFU-Mk increase in four patients. In vitro CFU-Mk assay suggest that some MDS patients are likely to benefit from the sequential addition of eltrombopag after azacitidine treatment, in the context of a personalized medicine.
机译：血小板减少症是骨髓增生异常综合征（MDS）患者的严重并发症。依曲波帕可增加MDS患者的血小板计数，但其与阿扎胞苷的联合使用引起了争议结果。我们的目的是量化从MDS患者和健康捐赠者分离的CD34+骨髓细胞中获得的巨核细胞（CFU Mk）的集落形成单位，这些细胞在有无氮胞苷的情况下在vitroin中培养，并在培养基中连续添加或不添加依曲波帕。6名MDS患者和3名对照组的CD34+骨髓细胞在体外扩增，并在添加或不添加氮胞苷的情况下培养3天。随后，在存在或不存在埃曲波帕的情况下进行CFU Mk分析。在对CD34+细胞进行模拟治疗后，在CFU-Mk试验中添加依曲波帕，可增加对照组和患者中的CFU-Mk数量。相反，使用阿扎胞苷预处理的CD34+细胞时，对照组中的依曲波帕最小程度地增加了CFU Mk，MDS患者中产生了异质性反应，两名患者没有变化，四名患者中CFU Mk增加。体外CFU-Mk分析表明，在个体化药物治疗的背景下，一些MDS患者可能受益于阿扎胞苷治疗后序贯添加依曲波帕。

著录项

  • 来源
    《Platelets》 |2021年第3期|共5页
  • 作者

    DAlo Francesco; Zangrilli Ilaria; Cupelli Elisa; Fianchi Luana; Criscuolo Marianna; Falconi Giulia; Fabiani Emiliano; Pagano Livio; Hohaus Stefan; De Stefano Valerio;

  • 作者单位

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Univ Roma Tor Vergata Dipartimento Biomed &

    Prevenz Rome Italy;

    Univ Roma Tor Vergata Dipartimento Biomed &

    Prevenz Rome Italy;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

    Fdn Policlin Univ Agostino Gemelli IRCCS Dipartimento Diagnost Immagini Radioterapia Oncol Rome;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 基础医学;
  • 关键词

    Azacitidine; eltrombopag; megakaryopoiesis; myelodysplastic syndromes;

    机译：氮杂氨酸;Eltrombopag;Megakaryopoiesis;myelodysplastic综合征;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号